Moore Capital Management LP Cuts Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Moore Capital Management LP reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 50.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 20,000 shares of the biotechnology company's stock after selling 20,000 shares during the period. Moore Capital Management LP's holdings in Ascendis Pharma A/S were worth $2,753,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ASND. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Crossmark Global Holdings Inc. raised its stake in Ascendis Pharma A/S by 28.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 10,435 shares of the biotechnology company's stock valued at $1,436,000 after acquiring an additional 2,315 shares during the last quarter. ARS Investment Partners LLC raised its stake in Ascendis Pharma A/S by 0.9% during the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company's stock valued at $36,549,000 after acquiring an additional 2,369 shares during the last quarter. SG Americas Securities LLC raised its stake in Ascendis Pharma A/S by 410.4% during the 4th quarter. SG Americas Securities LLC now owns 33,944 shares of the biotechnology company's stock valued at $4,673,000 after acquiring an additional 27,293 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 427 shares during the last quarter.

Ascendis Pharma A/S Stock Up 0.0%

Shares of ASND stock traded up $0.06 during mid-day trading on Friday, hitting $157.60. 502,233 shares of the company's stock were exchanged, compared to its average volume of 494,382. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The stock has a 50-day simple moving average of $156.91 and a two-hundred day simple moving average of $142.15. The stock has a market cap of $9.61 billion, a price-to-earnings ratio of -22.20 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Morgan Stanley raised Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $180.00 to $250.00 in a research note on Monday, May 5th. Evercore ISI upped their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Royal Bank of Canada increased their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.